Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05898399Phase 1Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Role: lead

NCT04657068Phase 1Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Role: lead

NCT04991480Phase 1Completed

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Role: lead

NCT05798611Phase 2Terminated

Study of ART0380 in Patients With Biologically Selected Solid Tumors

Role: lead

NCT04976803Completed

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

Role: lead

All 5 trials loaded